Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway

TALPHERA, INC.

Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.
Five clinical sites screening for NEPHRO CRRT study; two more expected in Q4; study completion anticipated in 2025.
Combined R&D and SG&A expenses $3.7M, up from $3.4M, driven by NEPHRO study costs.
DSUVIA divestment classified as discontinued operations; no related expenses in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.